Core Viewpoint - Femasys Inc. has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement of $1.00 per share, now having until July 13, 2026, to meet this requirement [1][2]. Company Compliance Status - The extension does not affect the continued listing status of Femasys' common stock on Nasdaq, and compliance will be confirmed if the stock price remains at or above $1.00 for ten consecutive business days [2]. - Femasys is committed to regaining compliance and plans to monitor its share price closely, taking necessary actions within the extension period [3]. Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally, with a patent-protected portfolio of therapeutic and diagnostic products [4]. - The company's fertility portfolio includes FemaSeed, which is over twice as effective as traditional IUI, and FemVue, a diagnostic tool for fallopian tube assessment [4]. - FemBloc, a non-surgical permanent birth control method, received regulatory approval in Europe, the UK, and New Zealand in 2025, and is being commercialized through strategic partnerships [5].